Page last updated: 2024-12-06
pro-diazepam
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
pro-diazepam: diazepam prodrug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71968 |
| CHEMBL ID | 2103985 |
| CHEBI ID | 2940 |
| SCHEMBL ID | 34243 |
| MeSH ID | M0179463 |
Synonyms (26)
| Synonym |
|---|
| 65617-86-9 |
| avizafone |
| avizafona [inn-spanish] |
| 2'-benzoyl-4'-chloro-2-((s)-2,6-diaminohexanamido)-n-methylacetanilide |
| ro 03-7355/000 |
| avizafonum [inn-latin] |
| pro-diazepam |
| (2s)-2,6-diamino-n-[2-(2-benzoyl-4-chloro-n-methylanilino)-2-oxoethyl]hexanamide |
| CHEMBL2103985 |
| ro-037355000 |
| chebi:2940 , |
| 65nk71k78p , |
| avizafonum |
| unii-65nk71k78p |
| avizafone [inn:ban] |
| avizafona |
| avizafone [inn] |
| ro-03-7355/000 |
| avizafone [who-dd] |
| avizafone [mart.] |
| SCHEMBL34243 |
| (2s)-2,6-diamino-n-[2-(2-benzoyl-4-chloro-n-methyl-anilino)-2-oxo-ethyl]hexanamide |
| DTXSID90215868 |
| Q4829057 |
| (s)-2,6-diamino-n-(2-((2-benzoyl-4-chlorophenyl)(methyl)amino)-2-oxoethyl)hexanamide |
| AKOS040746599 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "), MB327 DMS reached plasma Cmax of 22μM at 12min with an elimination t1/2 of 22min." | ( Pharmacokinetic profile and quantitation of protection against soman poisoning by the antinicotinic compound MB327 in the guinea-pig. Bird, M; Docx, CJ; Fairhall, SJ; Flint, DP; Green, AC; Poole, SJC; Price, ME; Rice, H; Tattersall, JEH; Timperley, CM; Whiley, L, 2016) | 0.43 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " Here we have studied the pharmacokinetics of pralidoxime after its intramuscular injection alone or in combination with avizafone and atropine using an auto-injector device." | ( Pharmacokinetic analysis of pralidoxime after its intramuscular injection alone or in combination with atropine-avizafone in healthy volunteers. Abbara, C; Bardot, I; Diquet, B; Ferec, S; Lallement, G; Lelièvre, B; Rousseau, JM; Turcant, A, 2010) | 0.36 |
| "The injection of pralidoxime combination with atropine and avizafone provided a higher pralidoxime maximal concentration than that obtained after the injection of pralidoxime alone (out of bioequivalence range), while pralidoxime AUC values were equivalent." | ( Pharmacokinetic analysis of pralidoxime after its intramuscular injection alone or in combination with atropine-avizafone in healthy volunteers. Abbara, C; Bardot, I; Diquet, B; Ferec, S; Lallement, G; Lelièvre, B; Rousseau, JM; Turcant, A, 2010) | 0.36 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The aim of this study was to assess the relative bioavailability of diazepam after administration of diazepam itself or as a water-soluble prodrug, avizafone, in humans." | ( Bioavailability of diazepam after intramuscular injection of its water-soluble prodrug alone or with atropine-pralidoxime in healthy volunteers. Abbara, C; Bardot, I; Clair, P; Comets, E; Diquet, B; Lallement, G; Rousseau, JM; Turcant, A, 2009) | 0.35 |
| " The MDZ-pro/A oryzae protease system showed greater than 25-fold increase in absorption rate of MDZ across MDCKII-wt monolayers, compared to saturated MDZ." | ( Chirally Pure Prodrugs and Their Converting Enzymes Lead to High Supersaturation and Rapid Transcellular Permeation of Benzodiazepines. Cheryala, N; Cloyd, JC; Georg, GI; Kapoor, M; Rautiola, D; Siegel, RA, 2016) | 0.43 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| peptide | Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (18)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 27.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.28) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (11.11%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||